TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28288172

Group type: EXPERIMENTAL
Intervention: Intervention (mRDTs training and provision of mRDTs and AL)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1400
Study: 25002367

Group type: EXPERIMENTAL
Intervention: Startling acoustic stimulus
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-startling acoustic stimuli (get ready and go)
Number of subjects: 8
Study: 23338056

Group type: EXPERIMENTAL
Intervention: TAP block with 0.25% levobupivacaine 0.5 ml kg(‐1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wound infiltration with 0.2 ml kg(‐1) 0.25% levobupivacaine
Number of subjects: 57
Study: 21192750

Group type: EXPERIMENTAL
Intervention: Get Moving Web site intervention
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 221
Study: 19320980

Group type: EXPERIMENTAL
Intervention: Best Start intervention
Number of subjects: 1666

Group type: COMPARATOR
Intervention: Control (rest of the state)
Number of subjects: 1666
Study: 18386621

Group type: EXPERIMENTAL
Intervention: Embryonary peptides (EP) administered for 60 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Embryonary peptides (EP)
Number of subjects: 0
Study: 12553951

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid enriched 20% lipid emulsion (MCT:LCT:fish oil = 5:4:1, MLF541; Lipoplus) for 5 days postoperatively
Number of subjects: 30

Group type: COMPARATOR
Intervention: standard 20% fat emulsion (LCT; Intralipid)
Number of subjects: 30
Study: 10714908

Group type: EXPERIMENTAL
Intervention: E2-DSG (1.5 mg E2 for 24 days with 0.15 mg DSG for the last 12 days followed by a placebo tablet for 4 days)
Number of subjects: 376

Group type: COMPARATOR
Intervention: E2V-MPA (2 mg E2V for 21 days with 10 mg MPA for the last 10 days)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: E2-DSG
Number of subjects: 376

Group type: COMPARATOR
Intervention: E2V-MPA
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 376
Study: 9361328

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Haloperidol 4 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Haloperidol 6 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1549940

Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 44

Group type: COMPARATOR
Intervention: Thiopental-halothane
Number of subjects: 44
Study: 6532148

Group type: EXPERIMENTAL
Intervention: Problem solving training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Attention placebo control
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Coping with guilt and personal failure training
Number of subjects: 33
Study: 31343391

Group type: EXPERIMENTAL
Intervention: Vancomycin combined with Daptomycin
Number of subjects: 30
Study: 30340490

Group type: EXPERIMENTAL
Intervention: Community-based mechanisms (Mothers committees, Jaanch committees, Village Health and Sanitation Committees, Self-Help Groups)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Self-Help Groups
Number of subjects: 84
Study: 27829030

Group type: EXPERIMENTAL
Intervention: Point fixation target
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cross fixation target
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ring fixation target
Number of subjects: 29
Study: 24883319

Group type: EXPERIMENTAL
Intervention: Ropivacaine + Tramadol (50 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ropivacaine + Ketamine (50 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ropivacaine (Control)
Number of subjects: 36
Study: 21042930

Group type: EXPERIMENTAL
Intervention: Motivational Strengths Model bridging case management intervention (BCM)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard of care prison-administered discharge planning program (SOC)
Number of subjects: 104
Study: 20071289

Group type: EXPERIMENTAL
Intervention: CIPRO XR 1000 mg once daily
Number of subjects: 212

Group type: COMPARATOR
Intervention: CIPRO IR 500 mg twice daily
Number of subjects: 212
Study: 16459272

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg IV over 2 min) + Naloxone (0.1 ng/kg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg IV over 2 min) + Naloxone (0.01 ng/kg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg IV over 2 min) + Naloxone (0.001 ng/kg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg IV over 2 min) + Normal Saline (Control)
Number of subjects: 156
Study: 15297901

Group type: EXPERIMENTAL
Intervention: 3 x 300 mg/day WS 5570
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 11345689

Group type: EXPERIMENTAL
Intervention: Salicis cortex extract with 240 mg salicin/day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Acetylsalicylate 100 mg/day
Number of subjects: 51
Study: 9215540

Group type: EXPERIMENTAL
Intervention: Legume consumption (120 gm mixed legumes substituted for foods with equivalent calories, fat, protein, and carbohydrate)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Legume consumption
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 9
Study: 8025207

Group type: EXPERIMENTAL
Intervention: Glipizide plus intensive insulin treatment (Group B)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intensive insulin treatment alone (Group A)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (overall)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: All patients (C-peptide levels)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Patients not entering remission (C-peptide levels)
Number of subjects: 27
Study: 3631495

Group type: EXPERIMENTAL
Intervention: Midazolam (5-7.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Meperidine (50-75 mg) and Promethazine (25-50 mg)
Number of subjects: 60
Study: 67338

Group type: EXPERIMENTAL
Intervention: D-penicillamine, 900 mg daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: D-penicillamine (for 4 patients over a year)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (for 7 patients with serial liver-copper measurements)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 27
Study: 31802733

Group type: EXPERIMENTAL
Intervention: Community-wide treatment (CWT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: School-based treatment (SBT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined arms of villages that received four rounds of treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: School-based treatment (SBT) for first-year primary students and adults
Number of subjects: 150
Study: 31684847

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) under level 1A evidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) under level 2B evidence
Number of subjects: 0

Group type: COMPARATOR
Intervention: No EVT offered under level 1A evidence
Number of subjects: 0
Study: 27761633

Group type: EXPERIMENTAL
Intervention: Pneumatic lithotripters (group-1)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Ho:YAG laser lithotripters (group-2)
Number of subjects: 267
Study: 26720025

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus triptorelin (LHRHa group)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 281
Study: 22936210

Group type: EXPERIMENTAL
Intervention: Knee model with skin holes left by peers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Knee model with no marks in the skin (control)
Number of subjects: 60
Study: 21188413

Group type: EXPERIMENTAL
Intervention: Lowest tertile of skin autofluorescence (AF)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Middle tertile of skin autofluorescence (AF)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Highest tertile of skin autofluorescence (AF)
Number of subjects: 232
Study: 19737046

Group type: EXPERIMENTAL
Intervention: Hyperhydration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Euhydration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypohydration
Number of subjects: 8
Study: 17253878

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) with serotonergic properties (e.g., carbamazepine, oxcarbazepine, valproate, lamotrigine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenobarbital and phenytoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other AEDs (e.g., topiramate, tiagabine, vigabatrin, levetiracetam, zonisamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study: 14999565

Group type: EXPERIMENTAL
Intervention: High-resolution magic angle spinning (HR MAS) MR spectroscopy
Number of subjects: 16
Study: 11573114

Group type: EXPERIMENTAL
Intervention: Doxycycline (200mg single dose followed by 100mg daily for 6 days)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Sulphadoxine/Pyrimethamine (1500mg sulphadoxine and 75mg pyrimethamine as a single dose)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Combination therapy of Sulphadoxine/Pyrimethamine and Doxycycline
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 280
Study: 9042046

Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg/m2 body area)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7949107

Group type: EXPERIMENTAL
Intervention: UVB-irradiated pooled platelets
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard pooled platelets (control group)
Number of subjects: 101
Study: 3239618

Group type: EXPERIMENTAL
Intervention: Digital fluid pressure monitor
Number of subjects: 8

Group type: COMPARATOR
Intervention: Needle manometer technique
Number of subjects: 8
Study: 30352668

Group type: EXPERIMENTAL
Intervention: Integrated Dual Diagnosis Treatment (IDDT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: IDDT training for clinicians
Number of subjects: 154
Study: 28441974

Group type: EXPERIMENTAL
Intervention: PM+ Group intervention (5 sessions, 3 hours each)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: PM+ Group intervention
Number of subjects: 612
Study: 26025097

Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI) 2 mg every 8 weeks (after 3 monthly doses; 2q8)
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI) 0.5 mg every 4 weeks (0.5q4)
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg every 4 weeks (Rq4)
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI) 2 mg every 8 weeks (2q8)
Number of subjects: 2457
Study: 24135273

Group type: EXPERIMENTAL
Intervention: Increased knee joint loading (Loaders)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Reduced knee joint loading (Unloaders)
Number of subjects: 157
Study: 21263078

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Information Control (IC)
Number of subjects: 79
Study: 19055281

Group type: EXPERIMENTAL
Intervention: Warming needle therapy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 117

Group type: COMPARATOR
Intervention: Medication (Salicylazosulfapyridine and Azathiopurine)
Number of subjects: 117
Study: 16735709

Group type: EXPERIMENTAL
Intervention: RT with concomitant TMZ followed by adjuvant TMZ
Number of subjects: 573

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 573
Study: 14739418

Group type: EXPERIMENTAL
Intervention: Aphasia therapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Controls (N=3)
Number of subjects: 3
Study: 11710652

Group type: EXPERIMENTAL
Intervention: Single-set strength training (1 set of 6-9 repetitions until failure)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Multiple-set strength training (3 sets of 6-9 repetitions until failure, rest interval 2 minutes)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nontraining control group
Number of subjects: 27
Study: 9401993

Group type: EXPERIMENTAL
Intervention: Three-dimensional ultrasonography
Number of subjects: 18

Group type: COMPARATOR
Intervention: Two-dimensional ultrasonography
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional prediction methods
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fetal volume parameters
Number of subjects: 18
Study: 8273399

Group type: EXPERIMENTAL
Intervention: Betamethasone-L-carnitine combination (4 g/5 days of L-carnitine and 2 mg/1 day of betamethasone)
Number of subjects: 109

Group type: COMPARATOR
Intervention: High dose betamethasone (8 mg/2 days)
Number of subjects: 109
Study: 3034062

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (25, 50, 100, or 200 micrograms/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transdermal estradiol (50 micrograms patch)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transdermal estradiol (100 micrograms patch)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (all doses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conjugated equine estrogen (0.625 mg and 1.25 mg)
Number of subjects: 50
Study: 31326308

Group type: EXPERIMENTAL
Intervention: Gadoxetic Acid enhanced MRI
Number of subjects: 20
Study: 29697993

Group type: EXPERIMENTAL
Intervention: Working memory training combined with recollection training based on the repetition‐lag procedure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard memory training (active control group)
Number of subjects: 36
Study: 26690370

Group type: EXPERIMENTAL
Intervention: E-mail messages
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Fax messages
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: SMS messages
Number of subjects: 848

Group type: COMPARATOR
Intervention: No-message control group
Number of subjects: 848
Study: 24750838

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/(m(2)·d), Qd) for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 23803270

Group type: COMPARATOR
Intervention: Manual lymphatic drainage (MLD) for 40 minutes
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT) for 20 minutes
Number of subjects: 46

Group type: COMPARATOR
Intervention: 20 minutes of MLD followed by 20 minutes of LLLT
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: LLLT with bandaging
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Compression bandaging alone
Number of subjects: 46
Study: 19827012

Group type: EXPERIMENTAL
Intervention: Weighted logrank (WLR) test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted Kaplan-Meier (WKM) test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Versatile tests combining WLR and WKM
Number of subjects: 0
Study: 19133098

Group type: EXPERIMENTAL
Intervention: Mtwo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 90

Group type: COMPARATOR
Intervention: NiTi-hand files
Number of subjects: 90
Study: 16550737

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg) from Laboratórios Cristália Ltd.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cozaar (50 mg) from Merck Sharp & Dohme Farmacêutica Ltd.
Number of subjects: 25
Study: 14636902

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg/day)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 10819825

Group type: EXPERIMENTAL
Intervention: 3‐day diet containing at least 150 g carbohydrate per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: No dietary restrictions
Number of subjects: 20
Study: 8859396

Group type: EXPERIMENTAL
Intervention: High goal group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low goal group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 1363488

Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl (2 micrograms/kg) and vecuronium (120 micrograms/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Atropine (control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Propofol (induction agent)
Number of subjects: 38
Study: 6585733

Group type: EXPERIMENTAL
Intervention: 3-mg prostaglandin E2 (PGE2) vaginal suppository
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31733777

Group type: EXPERIMENTAL
Intervention: Conventional treatment combined with core muscle strengthening exercises (Experimental Group)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional treatment alone (Control Group)
Number of subjects: 113
Study: 30672175

Group type: EXPERIMENTAL
Intervention: Combination group (flipping moxibustion + acupuncture)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Flipping moxibustion group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 120
Study: 27117602

Group type: EXPERIMENTAL
Intervention: Familiarity (6 hours exposure)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Negative stereotype (depiction as messy and clumsy)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No prior exposure (control for familiarity)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No stereotype (control for stereotype)
Number of subjects: 145
Study: 25301045

Group type: EXPERIMENTAL
Intervention: Dual-energy coronary CT angiography
Number of subjects: 27

Group type: COMPARATOR
Intervention: Single-energy coronary CT angiography
Number of subjects: 27
Study: 22326696

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA) with additional stent placement on indication
Number of subjects: 400

Group type: COMPARATOR
Intervention: Supervised exercise therapy (SET)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 400

Group type: COMPARATOR
Intervention: SET
Number of subjects: 400
Study: 21189915

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: (S) Atenolol 25 mg once daily
Number of subjects: 60
Study: 17286093

Group type: EXPERIMENTAL
Intervention: Craniocervical flexion exercise (CCFEx) program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional cervical flexion exercise (CFEx) program
Number of subjects: 50
Study: 15622265

Group type: EXPERIMENTAL
Intervention: Perlane
Number of subjects: 68

Group type: COMPARATOR
Intervention: Zyplast
Number of subjects: 68
Study: 12381038

Group type: EXPERIMENTAL
Intervention: VRGET with no physiological feedback (VRGETno)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VRGET with physiological feedback (VRGETpm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Imaginal exposure therapy (IET)
Number of subjects: 30
Study: 9928776

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at the level of the Gasserian ganglion
Number of subjects: 48
Study: 7550935

Group type: EXPERIMENTAL
Intervention: Cervical sympathetic ganglion block (CSB) with lidocaine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cervical sympathetic ganglion block (CSB) with bupivacaine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Cervical sympathetic ganglion block (CSB) with saline
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cervical sympathetic ganglion block (CSB) with lidocaine and bupivacaine
Number of subjects: 4
Study: 2147405

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Electronic monitor
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pill counts
Number of subjects: 21
Study: 6267651

Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study: 30489104

Group type: EXPERIMENTAL
Intervention: 90-day Facebook smoking cessation intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (Smokefree.gov referral)
Number of subjects: 500
Study: 28257937

Group type: EXPERIMENTAL
Intervention: CA: CHO + alpha-lactalbumin
Number of subjects: 10
Study: 27578364

Group type: EXPERIMENTAL
Intervention: Post-operative delirium assessment in PACU and within the first week after surgery.
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Cognitive function assessed with a neuropsychological test battery at 1 week and 3 months post-surgery.
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Multivariable analysis of POCD considering predisposing and precipitating factors.
Number of subjects: 850
Study: 24394594

Group type: EXPERIMENTAL
Intervention: Noise-reduction program (education, rules, technical devices)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no noise-reduction program)
Number of subjects: 156
Study: 22459241

Group type: EXPERIMENTAL
Intervention: Polyester suture augmentation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonaugmentation
Number of subjects: 100
Study: 19288469

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Globus pallidus interna (GPi) deep brain stimulation (DBS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ventral stimulation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Optimal DBS setting
Number of subjects: 52

Group type: COMPARATOR
Intervention: Off DBS
Number of subjects: 52
Study: 17961204

Group type: EXPERIMENTAL
Intervention: PS-FO
Number of subjects: 21

Group type: COMPARATOR
Intervention: PS-SO
Number of subjects: 21

Group type: COMPARATOR
Intervention: PS-OO
Number of subjects: 21
Study: 15995005

Group type: EXPERIMENTAL
Intervention: Vancomycin-heparin lock solution (25 microg/mL)
Number of subjects: 85
Study: 12053828

Group type: EXPERIMENTAL
Intervention: Various treatments for solar keratoses (specific interventions not detailed in the abstract)
Number of subjects: 0